Learn about Research & Clinical Trials

Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty

Study Purpose

There are very few studies in the literature examining the frailty levels of diffuse parenchymal lung disease (DPLD) patients and its effect on their functional status despite the high prevalance of frailty in patients with DPLD This observational study aims to learn about the relationship between frailty and functional capacity and balance in DPLD patients compared to healthy subjects.

Recruitment Criteria

Accepts Healthy Volunteers Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms	Yes
Study Type An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies.	Observational
Eligible Ages	30 Years - 65 Years
Gender	All

More Inclusion & Exclusion Criteria

Inclusion Criteria:

- Being diagnosed with Diffuse parenchymal lung according to the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria, - Being between the ages of 30-65, - Being literate, - Being willing to participate in the research, - Being clinically stable and having any accompanying comorbid conditions (such as hypertension, diabetes) under control, - Not having any orthopedic, metabolic or neurological problems that may prevent evaluation of peripheral muscle strength, balance and exercise capacity.

Exclusion Criteria:

- Having recently experienced syncope, - Having a history of unstable cardiovascular disease, - Having been hospitalized due to exacerbation in the last 3 months, - Having received pulmonary rehabilitation in the last 12 months, - Having a neurological disease, - Being dependent and using a walking aid while performing the person's daily life activities, - Having a pacemaker, - Having a diagnosis of lung cancer

Trial Details

Trial ID: This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.	NCT06171425
Phase Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.
Lead Sponsor The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.	Hacettepe University
Principal Investigator The person who is responsible for the scientific and technical direction of the entire clinical study.	N/A
Principal Investigator Affiliation	N/A
Agency Class Category of organization(s) involved as sponsor (and collaborator) supporting the trial.	Other
Overall Status	Not yet recruiting
Countries	Turkey
Conditions The disease, disorder, syndrome, illness, or injury that is being studied.	Diffuse Parenchymal Lung Disease, Frailty, Physical Inactivity

Additional Details

The aim of the study is to evaluate the relationship between the level of frailty and exercise capacity, respiratory functions, diffusion capacity, balance level, postural changes, activities of daily living, peripheral muscle strength and quality of life parameters in DPLD patients. The second aim is to compare diffuse parenchymal lung patients and the healthy control group in terms of these parameters.

Arms & Interventions

Arms

: DPAH group

patients with diffuse parenchymal lung diseases

: control group

aged matched healthy patients

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.